We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Andrew Blauvelt

Andrew Blauvelt MD, MBA

President, Oregon Medical Research Center, Portland, Oregon

Andy Blauvelt is President of Oregon Medical Research Center in Portland, Oregon, a private dermatology clinical studies business. He received his undergraduate degree in Electrical Engineering at Purdue University, his medical degree at Michigan State University, and his Healthcare MBA from Portland State University/Oregon Health & Science University (OHSU). Dr. Blauvelt trained in dermatology at the University of Miami and in cellular immunology under the direction of Steve Katz at the National Institutes of Health (NIH). He has held senior staff tenured positions at the NIH, OHSU, and the Portland VA Medical Center. Andy’s clinical and research expertise is in immunology, psoriasis, atopic dermatitis, and biologic therapies for complex medical dermatology patients, having published over 300 papers and spoken across the world on these topics. Dr. Blauvelt is also an elected member of the American Society for Clinical Investigation (a leading society for physician-scientists), the International Psoriasis Council (the premier group of psoriasis experts in the world), and the International Eczema Council (the premier group of eczema experts in the world).

Disclosures

Dr. Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Almirall, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma.